Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales

On Thursday, Elanco Animal Health Incorporated (NYSE:ELAN) reported third-quarter revenue of $1.03 billion, a decrease of 4% on a reported basis or a 1% organic constant currency growth, in line with the consensus.

The animal health company reported adjusted EPS of $0.13, down 28% year over year, beating the consensus of $0.12.

Also Read: Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy

Pet Health revenue was $486 million, a decrease of 2% on a reported and constant currency basis, primarily driven by competitive pressure on certain products in the U.S. veterinary channel, competitive pressure in Australia, and supply volatility for vaccines in the U.S., partially offset by increased sales of new products and improved demand for retail parasiticide products in the U.S. and Europe.

Farm Animal revenue fell 6% (+3% on constant currency) to $530 ...